Medicines for Europe to appeal the decision on its challenge to Urban Wastewater Treatment Directive. Medicines for Europe, which represents the generic and biosimilar industry, is fighting tooth and nail to address what it considers disproportionate costs that will be imposed on the pharma sector by the current extended producer responsibility (EPR) scheme embedded in the Urban Wastewater Treatment Directive (UWWTD).
Yesterday, Medicines for Europe announced its decision to challenge the Court of First Instance’s decision that it lacked legal standing to challenge the UWWTD. The technical decision meant that the Court did not address the substance of their arguments.
The Directive, which was adopted with little fanfare in 2024, has attracted growing controversy. Pharmaceuticals are one of the sectors – along with cosmetics – which have been identified in the legislation for an extended producer responsibility levy. ‘Extended producer responsibility’ will…
